Published in the September 2012 Newsletter

The ECOG-ACRIN Cancer Research Group has invited imagers from a variety of clinical settings and areas of expertise to participate in a day-long workshop to discuss the current state of oncologic imaging research and to share ideas on how to enhance site participation in imaging trials that answer scientific questions ranging from cancer screening and early detection to therapeutic interventions and post-treatment surveillance.

The 2012 Imaging Researchers’ Meeting, the first event of its kind, will be held on Thursday, October 4th at the Ritz Carlton Hotel in Pentagon City (Arlington, VA) The workshop is one of many outreach activities planned by ECOG-ACRIN to promote imaging research among institutions participating in federally funded cancer research sponsored by the National Cancer Institute (NCI).

Mitchell D. Schnall, MD, PhD, and Michael V. Knopp, MD, PhD, are serving as the co-chairs for the meeting. Dr. Schnall is Group Co-Chair of the ECOG-ACRIN Cancer Research Group and the Matthew J. Wilson Professor of Radiology and Associate Chair for Research in the Radiology Department at the University of Pennsylvania in Philadelphia.

Dr. Knopp is Professor of Radiology and Novartis Chair of Imaging Research; PI & Director, Wright Center of Innovation in Biomedical Imaging; and Vice Chair of Research in the Department of Radiology at the Wexner Medical Center at The Ohio State University in Columbus. Dr. Knopp also leads the imaging core laboratory for the Alliance for Clinical Trials in Oncology.

The meeting will feature separate, concurrent programs for technologists and investigators. Presenters will include imaging research experts affiliated with ECOG-ACRIN and other groups within the National Clinical Trials Network (NCTN), along with NCI representatives.

The programs and tentative agendas are as follows:

Workshop for Technologists – appropriate for lead technologists (computed tomography, positron emission tomography, and magnetic resonance imaging)

Tentative agenda:

  • Significance of imaging research results
  • Imaging research from the patient’s perspective
  • Clinical research basics and good clinical practices (human subject protection regulations, informed consent, clinical trial phases, FDA-1572, source documentation in clinical trials, etc.)
  • The importance of following the protocol in clinical trials
  • Imaging quality assurance from the ACRIN core lab (common imaging issues, case examples of excellent imaging, case examples of poorly executed imaging)
  • The importance of minority recruitment in research trials

Leadership Forum for Investigators – appropriate for radiologists, nuclear medicine physicians, and physicists

Tentative agenda:

  • The role of imaging in oncology trials (imaging as a biomarker, methods for the evaluation of imaging biomarkers, imaging in radiation therapy, imaging screening and surveillance)
  • Performance of advanced imaging in clinical trials
  • Panel discussion on prioritization of cancer marker development
  • Programs advancing imaging research and their research priorities (NCI-Cancer Imaging Program, Cancer Therapy Evaluation Program Imaging Steering Committee, Quantitative Imaging Biomarkers Alliance, Quantitative Imaging Network, Foundation for the National Institutes of Health, The Cancer Imaging Archive)
  • Current and future priorities across the NCI NCTN

All participants will join together over lunch for a panel discussion on what it takes to be a successful imaging research site. Representatives from the academic setting will share perspectives on site qualification and imaging quality, collaboration, and financial considerations. Panelists from community-based sites will share their experiences on such issues as procuring internal resources, obtaining organizational buy-in, and how to effectively communicate the benefits of imaging research within a community-based group.

Michael Knopp

Dr. Michael Knopp

Dr. Mitchell Schnall

Dr. Mitchell Schnall